A Case of Hemolytic Uremic Syndrome in a Lung Cancer Patient Treated with Gemcitabine / 결핵및호흡기질환
Tuberculosis and Respiratory Diseases
;
: 207-211, 2012.
Artigo
em Coreano
| WPRIM
| ID: wpr-154555
ABSTRACT
Hemolytic uremic syndrome (HUS) is a rare disorder characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. HUS arises from a wide spectrum of conditions, and chemotherapeutic agents have been reported to be associated with HUS, including Mitomycin, Cisplatin, Bleomycin, and Gemcitabine. A 76-year-old man treated with Gemcitabine due to non-small cell lung cancer developed clinical and laboratory findings compatible with HUS. Gemcitabine was ceased and hemodialysis and plasma exchange were utilized and he recovered. A high level of suspicion for HUS is necessary when cancer patients are treated with Gemcitabine, and prompt recognition and treatment are also essential.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Troca Plasmática
/
Trombocitopenia
/
Bleomicina
/
Diálise Renal
/
Cisplatino
/
Mitomicina
/
Carcinoma Pulmonar de Células não Pequenas
/
Desoxicitidina
/
Injúria Renal Aguda
/
Síndrome Hemolítico-Urêmica
Limite:
Idoso
/
Humanos
Idioma:
Coreano
Revista:
Tuberculosis and Respiratory Diseases
Ano de publicação:
2012
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS